全球神经系统疾病药物市场 – 行业趋势及 2029 年预测

市场分析和规模                              

在全球范围内，神经系统疾病是导致死亡的主要原因。它被定义为中枢和周围神经系统疾病。这些疾病主要影响老年人口。它可能会发展并需要长期治疗。先天性神经系统异常出现在胚胎发育的早期阶段，可以在出生时发现。各种因素，如创伤性脑损伤、免疫问题、产后注射、脊髓损伤、肿瘤形成以及接触环境化学物质或毒物，都可能导致出生后获得性神经系统疾病。许多细菌、病毒、真菌和寄生虫疾病都会损害神经系统，导致神经系统疾病。

Data Bridge Market Research 分析称，2021 年神经系统疾病药物市场价值为 794 亿美元，预计到 2029 年将达到 1256 亿美元，在 2022 年至 2029 年的预测期内复合年增长率为 5.9%。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。

报告范围和市场细分

Market Definition

A neurological diseases occurs when any portion of the brain or nervous system malfunctions, causing physical and/or psychological symptoms. Neurological disorders are treated with a variety of medications, including antipsychotics, antiepileptics, anticholinergics, and analgesics. Furthermore, the drug that is prescribed is primarily determined by the patient's neurological condition. These medications aid in the management of neurological conditions, symptom reduction, and improved quality of life. Corticosteroids, which are widely used to treat multiple sclerosis and help reduce inflammation, are among the most commonly used neurological medications.

Neurological Disorder Drugs Market Dynamics

Drivers

• Growing geriatric population

The market’s growth is propelled by an increase in the geriatric population, which leads to the presentation of numerous neurological problems. Cerebrovascular disorders such as stroke and migraine affect people of all ages in countries including Germany, the United Kingdom, and Italy. In adults aged 45 to 84, France, Sweden, Greece, Denmark, and Russia have high rates of cerebrovascular illness. As per a study published in the NCBI in 2018, the prevalence of stroke in Singapore was 7.67 percent among persons aged 65 and up.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of dermatitis market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

• Rising awareness about early disease diagnosis

The neurological disorder drugs market is expected to grow due to rising awareness associated with early disease diagnosis through awareness campaigns by government regulatory bodies and private organizations, and market entry of efficient drugs in the near future, owing to the presence of a strong drug pipeline. As per a report published by the Pharmaceutical Research and Manufacturers of America (PhRMA) in April 2018, biopharmaceutical companies in the United States are currently developing 537 medications for various neurological illnesses. 95 drugs for brain tumors, 46 for chronic pain, and 92 for Alzheimer's disease are among them. Multiple sclerosis, migraines, amyotrophic lateral sclerosis, and Parkinson's disease are among the 30 illnesses being researched.

Furthermore, surging number of government initiatives to spread awareness and increasing prevalence of neurological diseases such as dementia will result in the expansion of neurological disorder drugs market. Along with this, sedentary lifestyle of people and will enhance the growth rate of the market.

Opportunities

• Development of new drugs   

Moreover, the market's growth is fueled by an increase in the development of new drugs. This will provide beneficial opportunities for the market growth. Brain injuries and neurological disorders are among the major causes of death around the world. As a result, researchers are pursuing chances to produce new medications that could improve the treatment of neurological disorders by altering glucose metabolism. For instance, Gero Discovery, a provider of novel therapeutic alternatives for neurodegenerative disorders, recently revealed the discovery of a prospective medicine that uses the technique of glucose metabolism alteration in stressed neurons to assist avoid neuronal death. To create novel treatments, companies in the neurological disorder drugs industry need work with qualified researchers.

• Increase in the number of research and development activities       

The increase in the number of research and development activities is estimated to provide various beneficial opportunities for the neurological disorder drugs market’s growth. New therapeutic techniques for the treatment of Parkinson's disease are being adopted by companies in the neurological disorder pharmaceuticals market. This leads to high number of research activities to better understand the disease's genetic risk factors in order to find better drugs. As a result, mutations in the GBA1 gene are emerging as a prospective therapeutic development strategy. Mutations in the gene, however, may cause GCase (glucocerebrosidase) enzyme deficiencies. As a result, manufacturers in the neurological disorder pharmaceuticals market are concentrating on activating wild type GCase in order to produce new therapeutic molecules for the treatment of Parkinson's disease.

Moreover, the market's growth is fueled by rising investment for the development of advanced technologies and increase in the number of emerging markets. These factors will provide beneficial opportunities for the neurological disorder drugs market growth.

Restraints/Challenges

On the other hand, high cost associated with the research and development activities will obstruct the growth rate of market. The lack of healthcare infrastructure in developing economies and dearth of skilled professionals will challenge the neurological disorder drugs market. Additionally, product recalls and strict government regulations will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This neurological disorder drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the neurological disorder drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Neurological disorder drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Recent Development

• In September 2021, Sumitomo Dainippon Pharma and Otsuka had announced a collaboration as well as license agreement for four psychiatry and neurology compounds namely ulotaront (SEP-363856), SEP-4199, SEP-378614, and SEP-380135. Under the terms of the partnership, Sunovion and Otsuka will split the costs and revenues of clinical trials, regulatory applications, and commercialization in each of these nations and areas. Additional ulotaront indications, and also SEP-378614 and SEP-380135 indications, will be identified after future Sumitomo Dainippon Pharma Group and Otsuka consultations.

Global Neurological Disorder Drugs Market Scope

The neurological disorder drugs market is segmented on the basis of indication, drug class, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

指征

• 癫痫
• 阿尔茨海默病
• 帕金森病
• 多发性硬化症
• 脑血管病
• 其他的

药物类别

• 胆碱酯酶抑制剂
• NMDA 受体拮抗剂
• 抗癫痫
• 抗精神病和抗抑郁药
• 其他的

给药途径

• 口服
• 肠外
• 其他的

最终用户

• 医院
• 专科诊所
• 家庭护理
• 其他的

分销渠道

• 医院药房
• 零售药店
• 网上药店
• 其他的

神经系统疾病药物市场区域分析/见解

对神经系统疾病药物市场进行了分析，并按国家、适应症、药物类别、给药途径、最终用户和分销渠道提供了市场规模见解和趋势。

神经系统疾病药物市场报告涉及的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区（APAC）的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区（APAC）的其他地区、中东和非洲（MEA）的其他地区、南美洲的巴西、阿根廷和南美洲其他地区

北美在市场份额和市场收入方面占据神经系统疾病药物市场的主导地位，并将在预测期内继续保持主导地位。这是因为神经系统疾病的患病率很高，医疗支出的增加将进一步推动该地区市场的增长率。此外，主要关键参与者的不断增加以及 FDA 批准药物数量的增加将进一步推动该地区市场的增长率。

由于亚太地区仿制药制造商数量众多，预计该地区在 2022-2029 年的预测期内将实现增长。此外，医疗基础设施的发展和政府举措的不断增加将进一步推动该地区市场的增长率。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

竞争格局和神经系统疾病药物市场份额分析

神经系统疾病药物市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对神经系统疾病药物市场的关注有关。

神经系统疾病药物市场的一些主要参与者包括：

• 默克集团（德国）
• 卫材株式会社（日本）
• 阿斯利康（英国）
• 赛诺菲（法国）
• 诺华公司（瑞士）
• 雅培（美国）
• F. Hoffmann-La Roche Ltd.（瑞士）
• Teva Pharmaceutical Industries Ltd.（爱尔兰）
• 辉瑞公司（美国）
• 葛兰素史克公司 (英国)
• 沃克哈特（孟买）
• 诺和诺德公司（丹麦）
• Glenmark 制药有限公司（印度）
• Cipla Inc.（美国）
• Bausch Health Companies Inc.（加拿大）
• 大冢美国制药公司（美国）
• 强生私人有限公司（美国）
• 武田药品工业株式会社 (日本)
• 住友公司（日本）
• Biocon（印度）

SKU-53290